Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This is a prospective, pilot, single-arm, single-center study exploring the efficacy and
safety of savolitinib plus docetaxel as second-line therapy in patients with MET
overexpressed, EGFR/ALK/ROS1/MET ex14m-wildtype advanced NSCLC.
Participants will receive treatment of docetaxel (60 mg/m2, ivgtt, q3w) in combination with
savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after
informed consent signed. Treatment will continue until either objective disease progression,
unacceptable toxicity occurs, consent is withdrawn, other discontinuation criterion is met,
or study completion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University